Today: 3 July 2026

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

New York, Jan 29, 2026, 11:20 ET — During the regular session Eli Lilly shares climbed Thursday after Repertoire Immune Medicines announced a partnership with the drugmaker worth up to $1.93 billion, including an $85 million upfront payment, plus milestone and royalty fees. Lilly was up 0.5% at $1,028.89 in late morning trading, while the S&P 500 slipped about 1.4%. Repertoire will lead early research using its Decode platform, which explores how T cells attack diseased cells, before Lilly takes the programs to the clinic and eventually the market.
29 January 2026
····
1 … 351 352 353 354 355 … 877

Stock Market Today

  • Proteomics International (ASX: PIQ) Soars 28% on Friday as Investors React to Regulatory and Commercial Moves
    July 3, 2026, 12:16 AM EDT. Shares of Proteomics International Laboratories Ltd (ASX: PIQ) shot up 28.13% to AUD 0.20 on Friday after the company announced steps forward in its precision diagnostics and proteomics technology platform. The move comes as PIQ works on expanding its commercial footprint, securing regulatory clearances, and building up globally. The company said it's working to grow product adoption through new partnerships and continued research. Main push comes from recent regulatory progress, wider distribution, and more money going into new projects. But the company still faces regulatory risk, rivals, funding questions, and tough broader markets as a small-cap. Investors are tracking news on commercial deals and the next round of regulatory news that could move the stock again.
Go toTop